Welcome to our dedicated page for Vera Therapeutics SEC filings (Ticker: VERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vera Therapeutics filings document a Nasdaq-listed biotechnology company developing atacicept for serious immunological diseases, including IgA nephropathy. Form 8-K reports provide financial results, corporate updates, clinical and regulatory disclosures for the atacicept program, and material governance events such as board appointments, executive changes, and compensatory arrangements.
Proxy materials describe annual meeting matters, director elections, auditor ratification, advisory executive compensation votes, board committee structure, and related governance practices. The company’s filings also identify its Class A common stock registered on The Nasdaq Stock Market and disclose equity awards issued under director compensation and inducement grant arrangements.
VERA affiliate notified a proposed sale of 18,500 shares through a Form 144 filing.
The filing states 18,500 common shares are to be sold on 05/12/2026 following an exercise of stock options for cash. The excerpt also lists prior 10b5-1 sales by Marshall Fordyce: 22,951 shares on 04/14/2026 and 16,925 shares on 02/23/2026.
Vera Therapeutics reported a larger Q1 2026 loss as it ramped up spending to advance its lead kidney drug atacicept toward potential approval. Net loss widened to $121.0 million from $51.7 million a year earlier, driven by sharply higher research, manufacturing and commercialization costs.
Research and development expenses more than doubled to $86.0 million, including a $15.0 million milestone payment after the FDA accepted the Biologics License Application for atacicept in IgA nephropathy. General and administrative costs rose to $39.1 million as Vera built commercial and medical affairs capabilities. The company ended the quarter with $596.8 million in cash, cash equivalents and marketable securities and expects this to fund operations for at least 12 months. Atacicept’s Phase 3 trial met its proteinuria endpoint, and the FDA granted priority review with a PDUFA target action date of July 7, 2026.
Vera Therapeutics reported first-quarter 2026 results and highlighted progress toward potential FDA accelerated approval of atacicept for IgA nephropathy, which is under Priority Review with a PDUFA date of July 7, 2026. The company posted a net loss of $121.0 million, or $1.69 per share, compared with a net loss of $51.7 million, or $0.81 per share, a year earlier as research and development and general and administrative spending rose sharply. Vera ended March 31, 2026 with $596.8 million in cash, cash equivalents and marketable securities and believes this, together with its debt facility, will fund operations through potential atacicept approval and U.S. commercial launch and beyond.
Vera Therapeutics, Inc. President and CEO Marshall Fordyce reported open‑market sales of Class A Common Stock on April 14, 2026. He sold 14,130 shares at an average price of $43.6649, 7,921 shares at $44.5784, and 900 shares at $45.5114, totaling 22,951 shares sold.
These transactions were executed pursuant to a pre‑arranged Rule 10b5‑1(c) trading plan adopted on January 9, 2026. Following the sales, Fordyce directly holds 235,244 shares. He also has indirect holdings of 122,949 shares through a GRAT and 99,081 shares through a trust, which together include 1,032 shares acquired under the company’s 2021 Employee Stock Purchase Plan on March 13, 2026.
VERA reported a Form 144 notice showing a sale of 16,925 shares of Common Stock by Marshall Fordyce on 02/23/2026 for $710,577.51. The filing also lists 22,951 Restricted Stock Units dated 02/20/2026 as securities to be sold.
The sale is recorded on a Form 144 for Nasdaq-listed shares; the filing lists Morgan Stanley Smith Barney LLC as a broker/dealer contact. No additional proceeds treatment or holder limits are stated in the excerpt.
Vera Therapeutics, Inc. has called its 2026 Annual Meeting of Stockholders for May 21, 2026, to be held exclusively online via webcast. Holders of Class A common stock at the March 24, 2026 record date, when 71,713,905 shares were outstanding, may vote.
Stockholders will vote on electing three Class II directors to terms ending at the 2029 meeting, ratifying KPMG LLP as independent auditor for 2026, and approving an advisory "say‑on‑pay" resolution on executive compensation. The board recommends voting for all three proposals.
The proxy describes Vera’s classified 11‑member board, committee structure, and independence determinations, and details executive pay practices emphasizing performance‑based annual bonuses and multi‑year equity awards. It also outlines stock ownership of significant investors and insiders, governance policies (including a clawback and insider trading policy), and procedures for submitting future stockholder proposals and director nominations.
Vera Therapeutics, Inc. was reported as having 1,229,525 shares of Class A Common Stock beneficially owned by Point72-affiliated filers, representing 1.7% of the class as of March 31, 2026. The reported holdings include 17,800 shares issuable upon exercise of call options held by the managed fund. The filing is a joint Schedule 13G by Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen and states that the reporting persons have shared voting and dispositive power over the 1,229,525 shares.
Vera Therapeutics Inc ownership disclosure: The Vanguard Group amended its Schedule 13G to report 0 shares beneficially owned of Vera Therapeutics common stock, representing 0% of the class, following an internal realignment.
The filing states that on January 12, 2026 Vanguard reorganized and certain subsidiaries will report beneficial ownership separately in reliance on SEC Release No. 34-39538 (January 12, 1998). The amendment is signed by Ashley Grim on 03/27/2026.
Vera Therapeutics Chief Legal Officer Jane Wright-Mitchell received new equity awards. She was granted a stock option for 56,850 shares of Class A Common Stock at an exercise price of $40.73 per share, expiring on March 22, 2036.
She also received 42,403 restricted stock units under the 2024 Inducement Plan, representing 42,403 shares of Class A Common Stock. According to the vesting terms, one-fourth of the RSUs vest on each of May 20, 2027, 2028, 2029 and 2030, while the option vests 12/48ths on March 23, 2027 and 1/48th monthly thereafter, in each case contingent on continued service.